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Introduction
Mutations in BRCA1 and  BRCA2 account for approxi-
mately 50% of breast/ovarian cancer pedigrees with more
than four affected cases [1], whereas mutations in PTEN
[2], CHK2 [3] and ATM [4] have been reported in a small
number of breast cancer families or women with early onset
breast cancer. In addition, germ line missense mutations in
the p53 gene are associated with Li Fraumeni syndrome, a
ABCFS = Australian Breast Cancer Family Study; CI = confidence interval; kConFaB = Kathleen Cuningham Foundation for Research into Familial
Breast Cancer; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism.
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Abstract
Background: Mutations in BRCA1 and BRCA2 account for approximately 50% of breast cancer
families with more than four affected cases, whereas exonic mutations in p53, PTEN, CHK2 and ATM
may account for a very small proportion. It was recently reported that an intronic variant of p53 –
G13964C – occurred in three out of 42 (7.1%) ‘hereditary’ breast cancer patients, but not in any of
171 ‘sporadic’ breast cancer control individuals (P = 0.0003). If this relatively frequent occurrence of
G13964C in familial breast cancer and absence in control individuals were confirmed, then this would
suggest that the G13964C variant plays a role in breast cancer susceptibility.
Method: We genotyped 71 familial breast cancer patients and 143 control individuals for the
G13964C variant using polymerase chain reaction (PCR)-restriction fragment length polymorphism
(RFLP) analysis.
Results: Three (4.2%; 95% confidence interval [CI] 0–8.9%) G13964C heterozygotes were
identified. The variant was also identified in 5 out of 143 (3.5%; 95% CI 0.6–6.4%) control individuals
without breast cancer or a family history of breast cancer, however, which is no different to the
proportion found in familial cases (P = 0.9).
Conclusion: The present study would have had 80% power to detect an odds ratio of 4.4, and we
therefore conclude that the G13946C polymorphism is not a ‘high-risk’ mutation for familial breast cancer.
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feature of which is early onset breast cancer [5]. The p53
gene is the most commonly mutated gene in human malig-
nancies and has many important biological functions, includ-
ing the control of cell cycle checkpoint after DNA damage.
Deleterious germ line mutations in the p53 gene are found
in less than 1% of all breast cancer patients, suggesting
that the contribution of exonic mutations to familial breast
cancer risk is small [6–10]. However, mutations in regula-
tory regions of the gene may affect p53 expression and
thereby increase the risk of disease.
One candidate for such a mutation is the G13964C
variant in intron 6 of the p53 gene, which has been
reported in 3 out of 42 patients with hereditary breast
cancer (including a CC homozygote affected at age 59
years) but in none of 171 sporadic breast cancer patients
(P = 0.0003) [11]. All three patients with the p53 variant
had strong family histories that were consistent with Li
Fraumeni syndrome but had a late age at onset.
Intronic variants may affect gene regulation through aber-
rant splicing or through disruption of critical DNA–protein
interactions [12]. The p53 G13964C variant is not within
the consensus splice site and there is thus far no direct
evidence that it affects the expression of p53. It is not
associated with over-expression of p53 [13], which is a
hallmark of missense mutations in p53. Nonetheless, there
is some indirect evidence that this variant has a functional
role [11]. Functional analysis using an in vitro cell survival
assay demonstrated that lymphophoblastoid cell lines
derived from patients with the G13964C variant exhibited
a reduced level of apoptosis after chemotherapy and pro-
longed cell survival following DNA damage.
In order to determine the importance of the G13964C
p53 variant in multiple-case Australian breast cancer fami-
lies, we genotyped this variant in the youngest affected
member of 71 breast cancer families and 143 control indi-
viduals. Our results suggest that the rare 13964C allele is
no more common in breast cancer families than in control
individuals. This suggests that the variant is not a high-risk
mutation but, as suggested previously [13], is more likely
to be a benign polymorphism.
Materials and method
Familial breast cancer cases
Breast cancer cases were the youngest affected members
of multiple case families (n = 71), ascertained through
Family Cancer Clinics by the Kathleen Cuningham Foun-
dation Consortium for Research into Familial Breast
Cancer [14]. The Consortium entrance criteria for families
without known mutations in BRCA1 or BRCA2 are four or
more cases of breast or ovarian cancer (or two or more if
one has ‘high-risk’ features, such as diagnosis at less than
40 years) in the same or adjacent generations. All of the
families were tested by diagnostic laboratories for muta-
tions in BRCA1 and BRCA2 by a variety of tests (includ-
ing heteroduplex analysis, single strand conformation poly-
morphism, protein truncating test, chemical cleavage of
mismatch, allele specific oligonucleotide hybridization and
direct sequencing). It is estimated that most laboratories
would have detected approximately 80% of BRCA1 and
BRCA2 mutations (excluding the large deletions) by their
chosen methods.
Control individuals
Two separate control samples were included in this study.
The first group included individuals (n = 95) without breast
or ovarian cancer who were selected from the Australian
Breast Cancer Family Study (ABCFS), a population-based
case–control family study of breast cancer in women
recruited in Melbourne and Sydney from 1996 to 2000
[15]. These control women were aged 40–60 years (mean
49.7 years, SD 5.4 years) at interview, and had no first-
degree or second-degree relatives with breast cancer. The
second group comprised unrelated adult female mono-
zygotic twins (n = 48) who were selected from a sample
of 3348 twins of almost exclusively European descent,
recruited through the volunteer Australian Twin Registry
for the Semi Structured Assessment for the Genetics of
Alcoholism research study [16]. Age at interview ranged
from 30 to 75 years (mean 46.6 years, SD 11.9 years).
p53 G13964C variant analysis
A PCR-RFLP assay was used to detect the p53 intron 6
G13964C variant. A 131-bp PCR product was amplified
using 10 pmol of each primer (5′-GCCTCCCCT-
GCTTGCC-3′ forward primer and 5′-CCGCCCAT-
GCAGGAACT-3′ reverse primer) in a 10 µl reaction mix
containing 20 ng genomic DNA, 200 nmol/l dNTPs,
1 × Perkin Elmer PCR buffer II, 1U Taq  polymerase and
1.5 mmol/l MgCl2. Cycling conditions were 94°C for 4 min;
followed by four cycles of 94°C for 20 s, 60°C for 20 s and
72°C for 20 s; and 30 cycles of 94°C for 20 s, 58°C for
20 s, and 72°C for 20 s, with a final extension of 72°C for
7 min. Of the 131-bp amplified product, 3 µl was digested
with 4U of HhaI restriction enzyme (New England Biolabs)
in a 12 µl reaction with 1 × NEB Buffer4 and 1 × bovine
serum albumin (New England Biolabs, Beverley, MA, USA)
at 37°C for 1–2 h. The digested products were separated
on a 4% NuSieve agarose gel (Bio Whittacker Molecular
Applications, Rockland, ME, USA) and the genotype deter-
mined by the banding pattern observed.
Reaction products were sized relative to a BRL 1-kb
ladder (GIBCO BRL, Catalogue number 15615-016; Life
Technologies, Rockville, MD, USA). The GG genotype is
indicated by the presence of 33- and 98-bp fragments;
GC by 33-, 98- and 131-bp fragments; and the CC geno-
type, which lacks a HhaI restriction site, by a single 131-
bp product (Fig. 1). GC heterozygotes identified by the
restriction endonuclease assay were amplified andBreast Cancer Research    Vol 3 No 5 Marsh et al
sequenced using the primers described above and the
ABI Prism BigDye Terminator Cycle Sequencing Kit
(Perkin Elmer) for automated sequencing. 
Results
Screening with the PCR-RFLP assay identified the p53
intron 6 variant in 3 out of 71 (4.2%) heterozygote familial
breast cancer patients (diagnosed at the ages of 42, 43
and 48 years). None of these patients had family histories
indicative of Li Fraumeni syndrome, although their families
did include patients with cancer of the bone, pancreas,
cervix, stomach and prostate, as well as chronic lympho-
cytic leukaemia and non-Hodgkin’s lymphoma.
We also genotyped 143 control individuals without breast
or ovarian cancer. The rare allele was detected in 3 out of
95 (3.16%) ABCFS control individuals and in 2 out of 48
(4.17%) twin control individuals, resulting in a frequency in
pooled control women of 3.5%. This is not significantly dif-
ferent from the frequency in the familial breast cancer
cases (P = 0.9; Fisher’s exact test). The ABCFS control
individuals who were heterozygous for the G13964C
variant were aged 42–48 years at time of interview. None
of those women had a personal history of cancer, but two
had a family history of brain (age of onset 72 years), lung
or gastrointestinal cancer. The two heterozygous twin
control individuals, who did not have a personal or family
history of cancer, were aged 21 and 62 years. Direct
sequencing of seven heterozygote individuals confirmed
that the variation detected by the HhaI restriction endonu-
clease assay was due to a G→C nucleotide substitution
at position 13964.
Discussion 
The G13964C intronic variant was detected in eight indi-
viduals in total, none of whom had a family history of Li
Fraumeni syndrome. Because the G13964C intronic
variant was identified in individuals aged from 21 to 62
years with no evidence of cancer at the time of recruitment
and with no reported family history of breast cancer, the
present results suggest that this variant is not associated
with an increased risk for breast cancer. These findings
contradict the results found by Lehman et al [11], who did
not observe the variant in 171 sporadic breast cancer
control individuals and reported a significantly elevated
frequency in familial breast cancer. The present study
would have had 80% power to detect an odds ratio of 4.4,
and therefore we can conclude that the G13964C is not a
high-risk mutation for breast cancer. Instead, our results
support the proposal that the G13964C site is a benign
polymorphism, as originally suggested by Buller et al [13].
The variant lies within the noncoding region of the gene
and is not associated with over-expression of p53 [13].
In conclusion, although Lehman et al [11] reported that
the p53 G13964C variant acts to hinder chemotherapy-
induced apoptosis and extend cell survival following DNA
damage, these functional differences may not play a sig-
nificant role in the aetiology of breast cancer. Our data do
not provide any insights into the function of the
G13964C polymorphism at a cellular level, but they do
indicate that it is not significantly associated with familial
breast cancer in Australia.
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